Gliptins and Cardiovascular Outcomes: A Comparative and Critical Analysis after TECOS

Table 5

Upper bound 2-sided 95% confidence interval cut-off for approval [7].

≥1.8	Not approvable
1.3–<1.8	Approvable (large CV safety trial required)
<1.3	Approvable (postmarketing CV trial may not be required)